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Identity 
Other names: FKH1; FKHR; FOXO1A 




The FOXO1 gene extends approximately 110 kb and 
consists of 3 exons. 
Transcription 
Only a single transcript has been reported to be 
expressed from the FOXO1 gene, measuring 5.7 kb in 
length and containing an open reading frame of 1965 
bp. At the RNA level, the gene is widely expressed. 
Protein 
Description 
A single protein of 655 amino acids is expressed. This 
protein is a transcription factor with a forkhead box-
containing DNA binding domain in the N-terminal 
region and an acidic, serine/threonine-rich 
transcriptional activation domain in the C-terminal 
region. 
Expression 
The protein is widely expressed. Covalent attachment 
of ubiquitin moieties (polyubiquitination) targets 
FOXO1 protein for degradation, and thus FOXO1 
expression can be regulated by the ubiquitin-dependent 
proteasome. AKT is implicated in the regulation of 
FOXO1  
expression by its enhancement of FOXO1 
ubiquitination and proteolysis. 
Localisation 
The FOXO1 protein shuttles between the nucleus and 
cytoplasm. The subcellular localization and hence the 
transcriptional activity of FOXO1 is regulated by 
intracellular kinases. FOXO1 contains three AKT-
phosphorylation motifs [RxRxx(S/T)]. Phosphorylation 
of these sites by AKT promotes nuclear exclusion, 
association with 14-3-3 adaptor proteins and cytosolic 
retention. The serum and glucocorticoid-inducible 
kinase (SGK), dual-specificity tyrosine-phosphorylated 
regulated kinase DYRK1A and cyclin-dependent 
kinase 2 (CDK2) may also similarly phosphorylate 
FOXO1 and contribute to its subcellular localization, 
thereby acting combinatorially to suppress FOXO1 
transcriptional activity. Although the role of 
phosphatases in FOXO1 activation is unclear, PTEN 
may have a role in countering the effects of these 
kinases. 
Function 
FOXO1 plays an important role in many cellular 
processes. As a transcription factor, FOXO1 induces 
expression of target genes involved in apoptosis, 
glucose metabolism, cell cycle progression, and 
differentiation. There is increasing evidence of a role 
for FOXO1 as a tumor suppressor. FOXO1 
transcriptional responses are also implicated in cellular 
protection following DNA damage and oxidative stress, 
which may be related to a role in longevity. 
Homology 
The first FOX transcription factor fork head was  
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Figure 1. Diagram of t(2;13)(q35;q14) and t(1;13)(p36;q14) chromosomal translocations. 
 
identified in Drosophila. The subsequent cloning of 
mammalian FOX transcription factors revealed a 
common DNA-binding domain (forkhead box) that is 
highly conserved across species including Drosophila 
melanogaster, C. elegans and Homo sapiens. Within the 
larger FOX transcription factor family, there is a 
subfamily of which FOXO1 is the prototype. 
Additional members of this FOXO subfamily are: 
FOXO3 (FKHRL1, FOXO2), FOXO4 (AFX), FOXO6. 
A gene homologous to FOXO subfamily members, daf-
16, has also been identified in C. elegans and has 
facilitated analysis of the functional regulation of
mammalian FOXO subfamily members. FOXO 
members share consensus phosphorylation motifs for 
multiple kinases including AKT, CDK2, DYRK1A and 
SGK. Phosphorylation of these motifs regulates 
subcellular localization, DNA affinity, and protein-
protein interactions. Of note, three of the genes in the 
FOXO1 subfamily are involved in cancer associated-
chromosomal translocations. In addition to the 
rearrangement of FOXO1 in alveolar 
rhabdomyosarcoma (discussed below), FOXO3 and 
FOXO4 are joined with the MLL gene by 
translocations in acute myeloid leukemias. 
Mutations 
Germinal 
Inherited mutations of FOXO1 have not been 
identified. 
Somatic 
The FOXO1 gene is rearranged by the recurrent 
acquired chromosomal translocations - 
t(2;13)(q35;q14) and t(1;13)(p36;q14) - in the 
myogenic soft tissue cancer alveolar 
rhabdomyosarcoma. As a result of the 2;13 or 1;13 
translocation, portions of the PAX3 or PAX7 gene (on
chromosomes 2 or 1, respectively) are juxtaposed with
portions of the FOXO1 gene. In particular, the 5' region 
of PAX3 or PAX7, including the first seven exons of 
either gene, is joined to the 3' region of FOXO1, 
including its last two exons. Though the reciprocal 
chimeric gene is also generated, the PAX3-FOXO1 and 
PAX7-FOXO1 chimeric genes are more consistent and 
highly expressed, and result in expression of fusion 
proteins consisting of the intact PAX3 or PAX7 N-
terminal DNA binding domain fused in-framed to the 
intact FOXO1 C-terminal transcriptional activation 
domain.  
FOXO1 was identified as only gene within a minimal 
common region of deletion in chromosomal region 
13q14 in prostate carcinoma. FOXO1 deletion was 
detected in about 30% of prostate cancer samples, and 
additional cases were identified with reduced 
expression without evidence of deletion. Based on 
functional testing in prostate cancer cell lines that 
indicated that FOXO1 affected cell proliferation, 
survival, and androgen receptor signaling, the 
combined data indicates that FOXO1 is a tumor 
suppressor gene in prostate cancer. 
Implicated in 
Alveolar Rhabdomyosarcoma (ARMS) 
Disease 
ARMS is one subtype of a family of pediatric soft 
tissue tumors that is related to the skeletal muscle 
lineage. In contrast to embryonal rhabdomyosarcoma 
(ERMS), the other major subtype in this family, ARMS 
often occurs in adolescents and young adults, with 
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primary tumors located in the vicinity of skeletal 
muscle, such as in the extremities and trunk. 
Prognosis 
The overall prognosis for patients with ARMS is less 
favorable compared to those with ERMS. The three 
year survival rate for patients without metastatic 
disease was 66% (IRS-IV clinical trial), and evidenc  
of metastasis decreased the survival rate to only 16%. 
The pathogenesis of metastatic ARMS is associated 
with an early and wide dissemination, often involving 
bone marrow, and to poor response to chemotherapy. 
One study also indicates that for metastatic patients, 
tumors with a  
PAX3-FKHR fusion have a poorer outcome than 
tumors with a PAX7-FKHR fusion. In contrast, there is 
no reported difference in outcome between these 
subtypes in patients with non-metastatic tumors. 
Cytogenetics 
Translocations involving the q14 band on chromosome 
13 and the q35 band on chromosome 2 - 
t(2;13)(q35;q14) - distinguish ARMS from other soft 
tissue sarcomas. An additional 1;13 translocation - 
t(1;13)(p36;q14) - has been identified in a smaller 
number of ARMS cases. 
 
Figure 2. Generation of chimeric genes by the 2;13 and 1;13 translocations in ARMS. The exons of the wild-type and fusion genes are 
shown as boxes above each map and the translocation breakpoint distributions are shown as line segments below the map of the wild-
type genes. 
 
Figure 3. Comparison of wild-type and fusion products associated with the 2;13 and 1;13 translocations. The paired box, octapeptide, 
homeobox and fork head domain are indicated as open boxes, and transcriptional domains (DNA binding domain, DBD; transcriptional 
activation domain) are shown as solid bars. The sites phosphorylated by Akt are indicated by stars. The vertical dash line indicates the 
translocation fusion point. 
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Prostate carcinoma 
Disease 
Adenocarcinoma of the prostate is a malignant tumor 
arising from the glandular epithelium of the prostate 
gland. 
Prognosis 
In several studies in prostate cancer correlating 
outcome and chromosomal changes detected by allelic 
loss or comparative genomic hybridization, deletions r 
losses involving chromosomal region 13q14 were not 
found to be correlated with significant differences in 
outcome. 
Cytogenetics 
One of the most frequent deletions in prostate cancer 
involves the q arm of chromosome 13. There are two 
common regions of deletion in the q arm of 
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